HK Stock MarketDetailed Quotes

09926 AKESO

Watchlist
  • 69.400
  • -0.250-0.36%
Trading Nov 5 11:32 CST
62.29BMarket Cap-77282P/E (TTM)

About AKESO Company

Kangfang Biotechnology (Cayman) Co., Ltd. is a biopharmaceutical company dedicated to the research, development, production and commercialization of innovative antibody drugs that are affordable to patients around the world. Since its establishment, the company has established an end-to-end comprehensive drug development platform (ACE platform), covering fully integrated drug discovery and development functions, including target verification, antibody drug discovery and development, CMC production process development, and production in line with GMP standards. The company has also successfully developed bispecific antibody drug development technology (Tetrabody technology), which helps the company overcome the three CMC problems encountered in the development and production of bispecific antibodies, including inefficient expression levels, process development barriers, and antibody stability and pharmacogenicity. Up to now, the company has more than 50 research and innovation projects, covering various fields such as oncology, autoimmunity and metabolic diseases. Among them, 10 products are in the commercial or registered phase III clinical trial stage, including 41 self-developed products approved for marketing and 2 products under NMPA marketing review, and 12 novel drug molecules in phase I/II clinical research. 7 are potential first-in-class (first-in-class) or best-in-class (best-in-class) bispecific antibodies. The company hopes to become the world's leading biopharmaceutical company through efficient and innovative research and development, production of the pioneer/best-in-class bispecific antibody, and commercial platform construction.

Company Profile

Symbol09926
Company NameAKESO
ISINKYG0146B1032
Listing DateApr 24, 2020
Issue Price16.18
Shares Offered159.50M share(s)
FoundedJan 30, 2019
Registered AddressCayman Islands
Chairmanyu xia
Secretaryhuixin liang
Audit InstitutionErnst & Young
Company CategoryOther
Registered OfficeFloor 4, Willow House Cricket Square Grand Cayman KY1-9010 Cayman Islands
Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden Phase I, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees2815
MarketHong Kong motherboard
Phone(0760)89873998
Fax(0760)89873900
Emailir@akesobio.com
Business Kangfang Biotechnology (Cayman) Co., Ltd. is an investment holding company mainly engaged in the development of biological products. The company focuses on meeting outstanding global medical needs in oncology, immunization, and other treatments. The company's main products include AK104, AK105, AK112 and AK109. The company operates in the Chinese market and overseas markets.

Company Executives

  • Name
  • Position
  • Salary
  • yu xia
  • Presidencies, CEOs, President, Executive Director, Chairman of the Nomination Committee, Remuneration Committee Members, Authorized Representative
  • --
  • baiyong li
  • Executive Director, Senior Vice President, Chief Scientific Officer
  • --
  • zhongmin wang
  • Executive Director, Senior Vice President
  • --
  • yu xia
  • Senior Vice President
  • --
  • junwen ceng
  • Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members, Nomination Committee Members
  • --
  • yan xu
  • Independent Non-Executive Director, Nomination Committee Members, Remuneration Committee Members, Audit Committee Members
  • --
  • bai tan
  • Independent Non-Executive Director, Chairman of the Audit Committee
  • --
  • bingzhong wang
  • Chief Financial Officer
  • --
  • peng zhang
  • Executive Director
  • --
  • huixin liang
  • Joint Company Secretary, Authorized Representative
  • --
  • ronggang xie
  • Non-executive Directors
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data